ArchiveSee matrix →See on the body →ES
Peptide

Dasiglucagon

Glucagon analog that is stable in solution, in a ready-to-use autoinjector, to treat severe hypoglycemia in people with diabetes.
Regulatory status
Approved (FDA / EMA)
Family
Glucagon analog
Scientific evidence
High
Number of findings
1
Where it acts
Hormones and metabolism
Also known as
dasiglucagon, Zegalogue, ZP4207

Regulatory status

FDA (US): Approved (2021, Zegalogue) for severe hypoglycemia in patients with diabetes aged 6 years and older.

EMA (EU): Approved (2024, Zegalogue) for severe hypoglycemia in adults, adolescents, and children aged 6 years and older with diabetes.

Dose

0.6 mg by subcutaneous injection; if there is no response in 15 minutes, another dose can be given (FDA label 2021 / EMA 2024).

Safety

Frequent nausea and vomiting, headache, and discomfort at the injection site. It does not work if the liver has no glycogen reserves (prolonged fasting, alcohol). Contraindicated in pheochromocytoma and insulinoma.

Interactions

Beta-blockers may transiently increase heart rate and blood pressure; indomethacin may reduce its effect; it may increase the effect of warfarin.

Effect by goal · level of evidence

Recovery from severe hypoglycemia

improves High RCT (AA) in people
10 min vs 40 min

Phase 3 trial with 170 adults with type 1 diabetes and insulin-induced hypoglycemia. Glucose recovered in a median of 10 minutes with 0.6 mg of dasiglucagon, vs 40 minutes with placebo and 12 minutes with conventional glucagon. Nausea and vomiting were the most frequent effects.

View the study (RCT) →

In depth

Where it acts

Hormones and metabolism

Diabetes

How it works

It activates the glucagon receptor in the liver, which rapidly releases stored glucose (glycogen) into the blood. It has sequence changes that prevent it from aggregating, so it does not need to be reconstituted.

What the evidence says

In people

  • Recovery from severe hypoglycemia. Phase 3 trial with 170 adults with type 1 diabetes and insulin-induced hypoglycemia. Glucose recovered in a median of 10 minutes with 0.6 mg of dasiglucagon, versus 40 minutes with placebo and 12 minutes with standard glucagon. Nausea and vomiting were the most common effects. PubMed 35239971

References

  1. PubMed 35239971

Information, not medical advice. Prescription or unapproved peptides should only be used under medical supervision.

Loading assistant…